Terns Pharma (TERN) Investor Presentation - Slideshow

Obesity • ~$30B market5limited by supply/cost of peptides • Oral drugs expected to expand market access potential NASH • No approved drugs to date • Demand for drugs amenable for co-administration 2 Terns Pipeline: Broad Rights to Multiple Wholly-owned Opportunities Targeting Serious Diseases 1. Out-licensed to Hansoh Pharma (HS 10382) in the Greater China region; Ph 1 trial ongoing in China; Terns eligible for up to $ 67M in clinical, regulatory and sales-based milestones, mid single digit percentage royal ...